Predictors of hemoglobin response to eculizumab therapy in paroxysmal nocturnal hemoglobinuria

European Journal of Haematology

Volumn 90, Issue 1, 2013, Pages 16-24

  Dezern, Amy E ^a   Dorr, Donna ^a   Brodsky, Robert A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bone marrow failure; Eculizumab; Paroxysmal nocturnal hemoglobinuria

Indexed keywords

ANTICOAGULANT AGENT; ECULIZUMAB; GANCICLOVIR; HEMOGLOBIN; LACTATE DEHYDROGENASE; MENINGOCOCCUS VACCINE;

ADOLESCENT; ADULT; AGED; ANTICOAGULANT THERAPY; ARTERY THROMBOSIS; ARTICLE; BONE MARROW DEPRESSION; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DEEP VEIN THROMBOSIS; GOOD PARTIAL RESPONSE; HEMOLYSIS; HEMOLYTIC ANEMIA; HUMAN; INTRAVASCULAR HEMOLYSIS; MENINGOCOCCOSIS; MESENTERIC ARTERY THROMBOSIS; NEISSERIA MENINGITIDIS; OVERALL SURVIVAL; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOSIS; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HEMOGLOBINS; HEMOGLOBINURIA, PAROXYSMAL; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84871211318     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12021     Document Type: Article

References (19)

1. Rosse WF. Paroxysmal nocturnal hemoglobinuria as a molecular disease. Medicine (Baltimore) 1997;76:63-93.
2. Parker C, Omine M, Richards S, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood 2005;106:3699-709.
3. Brodsky RA. Narrative review: paroxysmal nocturnal hemoglobinuria: the physiology of complement-related hemolytic anemia. Ann Intern Med 2008;148:587-95.
4. Medof ME, Kinoshita T, Nussenzweig V. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J Exp Med 1984;160:1558-78.
5. Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA 2005;293:1653-62.
6. Lachmann PJ, Hughes-Jones NC. Initiation of complement activation. Springer Semin Immunopathol 1984;7:143-62.
7. Pangburn MK, Muller-Eberhard HJ. Relation of putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement. J Exp Med 1980;152:1102-14.
8. Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006;355:1233-43.
9. Brodsky RA, Young NS, Antonioli E, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 2008;111:1840-7.
10. Hillmen P, Elebute M, Kelly R, et al. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. Am J Hematol 2010;85:553-9.
11. Brodsky RA. How I treat paroxysmal nocturnal hemoglobinuria. Blood 2009;113:6522-7.
12. Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 2007;25:1256-64.
13. Hill A, Rother RP, Arnold L, Kelly R, Cullen MJ, Richards SJ, Hillmen P. Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization. Haematologica 2010;95:567-73.
14. Risitano AM, Notaro R, Marando L, et al. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood 2009;113:4094-100.
15. Brodsky RA, Mukhina GL, Li S, Nelson KL, Chiurazzi PL, Buckley JT, Borowitz MJ. Improved detection and characterization of paroxysmal nocturnal hemoglobinuria using fluorescent aerolysin. Am J Clin Pathol 2000;114:459-66.
16. Borowitz MJ, Craig FE, DiGiuseppe JA, Illingworth AJ, Rosse W, Sutherland DR, Wittwer CT, Richards SJ. Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry. Cytometry B Clin Cytom 2010;78:211-30.
17. Hillmen P, Muus P, Duhrsen U, et al. The terminal complement inhibitor eculizumab reduces thrombosis in patients with paroxysmal nocturnal hemoglobinuria (Abstract). Blood 2006;106:40a-1a.
18. Kelly RJ, Hill A, Arnold LM, Brooksbank GL, Richards SJ, Cullen M, Mitchell LD, Cohen DR, Gregory WM, Hillmen P. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood 2011;117:6786-92.
19. Fridkis-Hareli M, Storek M, Mazsaroff I, Risitano AM, Lundberg AS, Horvath CJ, Holers VM. Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of the human complement alternative pathway-mediated diseases. Blood 2011;118:4705-13.